Latest Content

In trials, the first oral PCSK9 inhibitor cut LDL cholesterol by up to 60%, which matched the efficacy of injectable PCSK9 therapies.

Smartphone remote monitoring captures between-visit symptom changes in myasthenia gravis, spotting week-to-week swings and enabling earlier symptom management than clinic visits.

FTC settles with CVS Caremark over insulin pricing, projecting $8.5 billion in patient savings over 10 years and mandating rebate and access reforms.

SNAP participation was linked to a smaller colorectal cancer screening gap among food-insecure US adults, ananalysis of 251,000 found.

Health system executives say Medicaid cuts, payer disputes, and misaligned incentives are driving the affordability crisis in 2026.

Respiratory rehabilitation improved exercise capacity in patients with COPD with and without suspected pulmonary hypertension.

Kerry Rogers, MD, at The James, unpacks what these questions mean for patient counseling and clinical trial equity in chronic lymphocytic leukemia (CLL).

Approval is granted for patients with PIK3CA wild-type disease who progressed after endocrine therapy, based on VIKTORIA-1's improved survival results.

New topicals, orals, and biologics are expanding chronic hand eczema treatment, but phenotype-specific data gaps remain.